
CryoPort (CYRX) Stock Forecast & Price Target
CryoPort (CYRX) Analyst Ratings
Bulls say
CryoPort is well-positioned to continue growing, with a strong focus on the emerging cell and gene therapy market. The company's global logistics network and partnerships with various commercial and clinical customers provide a strong platform for future revenue growth. Additionally, the company's cold storage and shipping technology, while impacted by the COVID-19 pandemic, is expected to continue growing in the coming years. These factors, combined with its high market share in the clinical trial market, make CryoPort a compelling investment opportunity.
Bears say
CryoPort is currently experiencing revenue growth and expects to see further expansion of revenue and margins through 2028. However, risks such as clinical trial success and macroeconomic pressures could negatively impact the company's growth. Additionally, the company's LT EBITDA margin target of ~30% may be too optimistic compared to its peers. Furthermore, while the company's current financial performance is strong, its valuation at ~14x FY28E EV/EBITDA is considered higher compared to its peers.
This aggregate rating is based on analysts' research of CryoPort and is not a guaranteed prediction by Public.com or investment advice.
CryoPort (CYRX) Analyst Forecast & Price Prediction
Start investing in CryoPort (CYRX)
Order type
Buy in
Order amount
Est. shares
0 shares